본문으로 건너뛰기
← 뒤로

Phenotypic Hit Identification and Optimization of Novel Pan-TEAD and Subtype-Selective Inhibitors.

Journal of medicinal chemistry 2025 Vol.68(22) p. 24603-24623

Heinrich T, Gambardella A, Schwarz D, Petersson C, Gunera J, Garg S, Schneider R, Keil M, Grimmeisen L, Unzue Lopez A, Schilke H, Weitzel T, Kolb C, Diehl P, Doerfel B, Anlauf U, Reither V, Rettig C, Opelt B, Delp A, Wildner N, Musil D, Friedrich E, Burgdorf L, Fuchss T, Albers L, Sousa PMF, Freire F, M Bandeiras T, Wienke D

📝 환자 설명용 한 줄

Aiming to identify novel inhibitors of YAP-TEAD-dependent transcription, we conducted a TEAD-reporter-based cellular screen, which yielded a 5-azaindole hit that significantly stabilized TEAD subtypes

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Heinrich T, Gambardella A, et al. (2025). Phenotypic Hit Identification and Optimization of Novel Pan-TEAD and Subtype-Selective Inhibitors.. Journal of medicinal chemistry, 68(22), 24603-24623. https://doi.org/10.1021/acs.jmedchem.5c02602
MLA Heinrich T, et al.. "Phenotypic Hit Identification and Optimization of Novel Pan-TEAD and Subtype-Selective Inhibitors.." Journal of medicinal chemistry, vol. 68, no. 22, 2025, pp. 24603-24623.
PMID 41212049

Abstract

Aiming to identify novel inhibitors of YAP-TEAD-dependent transcription, we conducted a TEAD-reporter-based cellular screen, which yielded a 5-azaindole hit that significantly stabilized TEAD subtypes 2 and 4 in a thermal shift assay. During optimization, derivatives with diverse TEAD selectivity profiles were obtained, including pan-TEAD and TEAD3-sparing inhibitors. Atropisomers with stabilized binding conformations surprisingly resulted in TEAD2 selective inhibitors. Cellular potency in reporter and viability assays was enhanced through targeted structural modifications. The physicochemical and pharmacokinetic properties were improved by the introduction of heteroatoms and the reduction of aromaticity. Structure-based considerations inspired the generation of a pyrrolo-pyridinone scaffold with further optimized properties. In lung cancer xenograft studies, representatives from both substance classes demonstrated monotherapeutic antitumor activity. For one selected example, the combination effect with the KRAS inhibitor was demonstrated in vivo.

MeSH Terms

Humans; Animals; Structure-Activity Relationship; Antineoplastic Agents; Transcription Factors; Cell Line, Tumor; Mice; Lung Neoplasms; Xenograft Model Antitumor Assays; TEA Domain Transcription Factors; Mice, Nude